BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data
I'm PortAI, I can summarize articles.
Structure Therapeutics shares rose 3% after Eli Lilly's promising trial data for its oral obesity pill, orforglipron. J.P. Morgan views Lilly's data positively for Structure's own oral pill, aleniglipron, with trial results expected in H2 2026. Structure's stock has increased 126% YTD, despite a previous 33.5% drop in 2024.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments